CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma...
Phase 1
Cincinnati, Ohio, United States and 4 other locations
mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...
Phase 2
Cincinnati, Ohio, United States and 44 other locations
participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignatur...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 66 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Cincinnati, Ohio, United States and 138 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Cincinnati, Ohio, United States and 165 other locations
unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...
Phase 3
Middletown, Ohio, United States and 219 other locations
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 6 other locations
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 12 other locations
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Phase 1, Phase 2
Cincinatti, Ohio, United States and 10 other locations
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant sol...
Phase 1
Cincinnati, Ohio, United States and 16 other locations
Clinical trials
Research sites
Resources
Legal